Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LOMITAPIDE Cause Therapeutic product effect incomplete? 7 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Therapeutic product effect incomplete have been filed in association with LOMITAPIDE (Juxtapid). This represents 0.2% of all adverse event reports for LOMITAPIDE.

7
Reports of Therapeutic product effect incomplete with LOMITAPIDE
0.2%
of all LOMITAPIDE reports
1
Deaths
3
Hospitalizations

How Dangerous Is Therapeutic product effect incomplete From LOMITAPIDE?

Of the 7 reports, 1 (14.3%) resulted in death, 3 (42.9%) required hospitalization.

Is Therapeutic product effect incomplete Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LOMITAPIDE. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does LOMITAPIDE Cause?

Diarrhoea (1,071) Therapy cessation (828) Weight decreased (828) Nausea (567) Abdominal pain upper (280) Flatulence (244) Abdominal discomfort (228) Vomiting (211) Off label use (206) Fatigue (200)

What Other Drugs Cause Therapeutic product effect incomplete?

ALBUTEROL (8,496) ADALIMUMAB (6,986) PREDNISONE (6,709) METHOTREXATE (6,037) TOFACITINIB (4,914) SECUKINUMAB (4,661) BUDESONIDE\FORMOTEROL (4,392) TIOTROPIUM (4,327) MEPOLIZUMAB (4,106) ETANERCEPT (3,961)

Which LOMITAPIDE Alternatives Have Lower Therapeutic product effect incomplete Risk?

LOMITAPIDE vs LOMUSTINE LOMITAPIDE vs LONAPEGSOMATROPIN-TCGD LOMITAPIDE vs LONCASTUXIMAB TESIRINE-LPYL LOMITAPIDE vs LOPERAMIDE LOMITAPIDE vs LOPINAVIR

Related Pages

LOMITAPIDE Full Profile All Therapeutic product effect incomplete Reports All Drugs Causing Therapeutic product effect incomplete LOMITAPIDE Demographics